Xanthine Oxidase Inhibition in Renal Transplant Recipients (XART)

NCT01332799 Phase 4 TERMINATED Results posted

Cardiovascular disease is the leading cause of mortality in kidney transplantation. The enzyme xanthine oxidase may play an important role in the cardiovascular disease of kidney transplant recipients. Inhibiting this enzyme with allopurinol may improve vascular health and protects against cardiovascular complications.

Details

Lead sponsor	Roberto S Kalil
Phase	Phase 4
Status	TERMINATED
Enrolment	20
Start date	2011-02
Completion	2018-08-10

Conditions

• Complications of Renal Transplant

Interventions

• allopurinol or placebo
• Placebo

Primary outcomes

• Cardiovascular Events — 3 years
  Number of major cardiovascular events
• Endothelial Function — 3 years
  Changes in flow-mediated dilatation of braquial artery.

Countries

United States